Non-specific serum binding to streptavidin in a biotinylated peptide based enzyme immunoassay

Insight into the human pathodegradome of the V8 protease from Staphylococcus aureus

Staphylococcus aureus possesses ten extracellular proteases with mostly unknown targets in the human proteome. To assist with bacterial protease target discovery, we have applied and compared two N-terminomics methods to investigate cleavage of human serum proteins by S. aureus V8 protease, discovering 85 host-protein targets. Among these are virulence-relevant complement, iron sequestration, clotting cascade, and host protease inhibitor proteins. Protein cleavage sites have been identified, providing insight into the disruption of host protein function by V8. Complement proteins are cleaved within peptidase and sushi domains, and host protease inhibitors are cleaved outside their protease-trapping motifs. Our data highlight the potential for further application of N-terminomics in discovery of bacterial protease substrates in other host niches and provide omics-scale insight into the role of the V8 protease in S. aureus pathogenesis.

S. aureus-secreted proteases are central to disease causation, but the discovery of their host substrates has been limited. Frey et al. use N-terminomic approaches to uncover human serum targets of the V8 protease that are from virulence-relevant processes such as the host inflammatory network and nutrient sequestration.

Functional Proteomic Profiling of Secreted Serine Proteases in Health and Inflammatory Bowel Disease

While proteases are essential in gastrointestinal physiology, accumulating evidence indicates that dysregulated proteolysis plays a pivotal role in the pathophysiology of inflammatory bowel disease (IBD). Nonetheless, the identity of overactive proteases released by human colonic mucosa remains largely unknown. Studies of protease abundance have primarily investigated expression profiles, not taking into account their enzymatic activity. Herein we have used serine protease-targeted activity-based probes (ABPs) coupled with mass spectral analysis to identify active forms of proteases secreted by the colonic mucosa of healthy controls and IBD patients. Profiling of (Pro-Lys)-ABP bound proteases revealed that most of hyperactive proteases from IBD secretome are clustered at 28-kDa. We identified seven active proteases: the serine proteases cathepsin G, plasma kallikrein, plasmin, tryptase, chymotrypsin-like elastase 3 A, and thrombin and the aminopeptidase B. Only cathepsin G and thrombin were overactive in supernatants from IBD patient tissues compared to healthy controls. Gene expression analysis highlighted the transcription of genes encoding these proteases into intestinal mucosae. The functional ABP-targeted proteomic approach that we have used to identify active proteases in human colonic samples bears directly on the understanding of the role these enzymes may play in the pathophysiology of IBD.

Evaluation of direct versus multi-layer passivation and capture chemistries for nanoparticle-based biosensor applications

Nanoparticles used in biosensor applications often fail when deployed directly in complex biological fluids. This is due to surface fouling and interference from the large concentration of non-specific binders (proteins, lipids, nucleic acids and saccharides) in the matrix. We systematically investigate four orthogonal approaches for decorating nanoparticle surfaces with affinity probes and evaluate their performance in buffer and serum. Carbodiimide coupling, cooper-mediated 'click' coupling, copper-free click coupling and thiol-maleimide coupling were quantitatively controlled during the fabrication process. Analyte mediated aggregation of fluorescent reporters and paramagnetic nanoparticle in a sandwich immunoassay was then used to probe assay sensitivity and specificity using an early biomarker of dengue fever, NS-1, as an exemplar and clinically relevant analyte. The type of surface functionalization played a vital role in assay performance in buffer versus serum at the assay sensitivity limit (3 ng/mL in serum) and over the linearity of response of the assay's dynamic range. There was a 10 fold increase on the dynamic range of the detection of NS1 comparing copper free click coupling to carbodiimide coupling, one of the most common approaches for nanoparticle functionalization. By tuning their size, we could carefully monitor the evolution of nanoparticle populations by flow cytometer and discriminate between unbound and fluorescent nanoparticles. This subtle control on each assay component resulted in more than a 10-fold reduction in fluorescence background and improved the sensitivity of almost two orders of magnitude compared to endpoint measurements.

A paramagnetic-reporter two-particle system for amplification-free detection of DNA in serum

Quantitative nucleic acid detection is used extensively in the management of many pathogenic infections, where viral or bacterial nucleic acid copy number relates directly to disease prognosis. Temperature-cycle or isothermal amplification formats offer excellent performance, but their requirement for purified nucleic acid and accurate temperature control increases costs and renders their migration to resource-limited environments problematic. In contrast, amplification-free nucleic acid assays could allow simplified system design, resulting in reduced costs. In this study, we report a amplification-free herpes simplex virus (HSV) assay where oligoethylene glycol methacrylate (OEGMA) grafted ssDNA capture-probes on paramagnetic nanoparticles are coupled with reporter-probe-modified fluorescent nanoparticles in a target-dependent manner. Following assay and reagent optimization, a sub-pM (25 amol) limit of detection could be achieved in buffer and also in neat, undiluted serum, representing a 160-fold improvement over that achieved using convention detection with a fluorescence plate reader. Equivalent performance in serum and buffer offers the opportunity for simplified diagnostic device design for resource-limited environments.

Reduction of non-specific binding in immunoassays requiring long incubations

Despite the studies so far about the non-specific binding of antibody molecule to the plastic of solid phase in enzyme-linked immunoassays, background binding in microwell Elisa continues to be a troublesome problem.Non-specific immunoglobulin from an undiluted serum sample can adhere to the surface of a 'blocked' plate to result in a maximal signal in an antigen capture assay for specific antibody to render analysis virtually impossible in undiluted serum when using labelled anti-species antibodies. Yet it is desirable in many circumstances that the maximum sensitivity achievable by the simple expedient of using a concentrated sample (undiluted serum) be exploited, for example in the analysis of antibodies to HIV in the interest of earlier diagnosis. To circumvent this problem we have developed an alternative strategy in which a biotinylated capture reagent is preincubated with the serum sample for the necessary time after which the biotinylated ligand/antibody complex is itself rapidly captured in streptavidin-coated wells at 4°C, with subsequent detection with labelled anti-species immunoglobulin. This manoeuvre enables the capture ligand to be incubated with undiluted serum sample for long time periods resulting in improved specificity of detection. By this means we describe a general method to improve the specificity of serum antibody immunoassays which will be expected to produce the benefit of more rapid diagnosis by signalling antibody production earlier in the abnormal state. Furthermore, our new method could be used to reduce non-specific binding in other immunological assays such as antibody arrays to which much attention has recently been paid.

No evidence of endemic Borna disease virus infection in Australian horses in contrast with endemic infection in other continents

Borna disease virus (BDV) is a unique RNA virus that is a cause of neurological disease in horses, sheep and cats. The finding that BDV also infects humans has raised concern related to the impact of infection with this virus. The extent to which BDV may be endemic in geographical regions outside Europe is of interest in management of international movement of animals including horses. Sera from Australian horses (N = 553) sampled in Sydney, New South Wales (NSW), were analysed for BDV antigen, circulating immune complexes (CICs), and antibodies by monoclonal antibody-based ELISAs. One-tenth of the samples were investigated by further antibody tests, namely immunofluorescence (IFA) and a peptide ELISA, as well as for BDV RNA. The study revealed a very low frequency of serological markers that may be associated with exposure to BDV in Australian horses from NSW with a few sera (0.7%) displaying low range positive results in the CIC assay, and no detectable BDV RNA. This pattern is inconsistent with endemic BDV infection and strongly contrasts with the pattern of endemic infection, particularly in Europe.

Effects of the competitor on antibody-hapten binding in immunoassays

The effects of competitors on antibody (Ab)-hapten binding in an immunoassay were investigated using a goat antimethamphetamine (MA) antibody (Ab). An N-4-aminobutyl derivative of methamphetamine (4-ABMA) was conjugated with keyhole limpet hemocyanine (KLH) and used as an immunogen. The antiserum was purified by affinity chromatography with various ligands, including 4-ABMA-protein conjugates, free haptens, and protein G. Direct and indirect competitive enzyme-linked immunosorbent assays (ELISA) were conducted with a competitor of 4-ABMA-fluorescein isothiocyanate (4-ABMA-FITC). The results were compared to those of ELISA with a different competing antigen, 4-ABMA-ovalbumin (4-ABMA-OVA), in terms of sensitivity and specificity. In both direct and indirect assay formats, the sensitivity was much improved with 4-ABMA-FITC, compared to that with 4-ABMA-OVA, suggesting that different labels on the same haptenic moiety for competitors considerably influence the assay performance. All the purified Abs also showed a distinct feature of strong affinity for benzphetamine with 4-ABMA-FITC, whereas they had their respective binding specificities with 4-ABMA-OVA. Comparing the results to those from other assay systems, we determined that the assay sensitivity was dependent on both the system and the competitor employed, and that the specificity was primarily dependent on the competitor used.